FluoroPharma Medical (OTCMKTS:FPMI – Get Free Report) and Zynex (NASDAQ:ZYXI – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.
Valuation & Earnings
This table compares FluoroPharma Medical and Zynex”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| FluoroPharma Medical | N/A | N/A | N/A | N/A | N/A |
| Zynex | $108.20 million | 0.04 | $2.99 million | ($2.43) | -0.05 |
Profitability
This table compares FluoroPharma Medical and Zynex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| FluoroPharma Medical | N/A | N/A | N/A |
| Zynex | -68.35% | -804.30% | -36.67% |
Risk & Volatility
FluoroPharma Medical has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Zynex has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for FluoroPharma Medical and Zynex, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| FluoroPharma Medical | 0 | 0 | 0 | 0 | 0.00 |
| Zynex | 1 | 2 | 1 | 0 | 2.00 |
Zynex has a consensus target price of $3.35, indicating a potential upside of 2,580.00%. Given Zynex’s stronger consensus rating and higher possible upside, analysts plainly believe Zynex is more favorable than FluoroPharma Medical.
Institutional & Insider Ownership
29.7% of Zynex shares are owned by institutional investors. 36.9% of FluoroPharma Medical shares are owned by insiders. Comparatively, 49.3% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Zynex beats FluoroPharma Medical on 7 of the 10 factors compared between the two stocks.
About FluoroPharma Medical
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.
About Zynex
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Receive News & Ratings for FluoroPharma Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FluoroPharma Medical and related companies with MarketBeat.com's FREE daily email newsletter.
